Suchergebnisse
Suchergebnisse:
THRESHOLD PHARMACEUTICALS REGISTERED AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Threshold Pharmaceuticals Registered Shs | A2DVLK | MTEM | US6085501095.
- Threshold Pharmaceuticals Registered informierte über die jüngsten ...
Threshold Pharmaceuticals Registered äußerte sich am...
- Threshold Pharmaceuticals Registered informierte über die jüngsten ...
Phone Number (650)474-8200. Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors.
- South San Francisco, California
- George F. Tidmarsh
- Threshold Pharmaceuticals is located in South San Francisco, California, United States.
- Threshold Pharmaceuticals has 14 investors including Cancer Prevention and Research Institute of Texas And Merck.
- Threshold Pharmaceuticals has raised $137.7M.
- Threshold Pharmaceuticals closed its last funding round on Mar 17, 2017 from a Post-IPO Equity round.
- Alternatives and possible competitors to Threshold Pharmaceuticals may include Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, And Apellis Ph...
Overview. Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors.
- 300 170 Harbor Way, South San Francisco, United States
- 300170,4B
7. Dez. 2015 · Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of ...
Threshold Pharmaceuticals, Inc. (ZB_4706838.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Threshold Pharmaceuticals, Inc. | Nasdaq: | Nasdaq c0ca4a1482aeb8ec9975d4f09.eN1xAmEwu0-NCOPrBMr0cIOuP6XspCilYMR0De4d2TE.QYobWyR_ige-b7a0MZurGdKYCuirkV7wKKFFfqx7vkdJhyVOVVvyDuk7gA
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, recently announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase III clinical trial in ...
